Orthocell (ASX:OCC) DeferredTaxAndRevenue: A$0.00 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:OCC Orthocell Ltd ASX:OCC
61 GF Score
Price A$0.73
GF Value A$1.55
Valuation Possible Value Trap
! 2 Warning Signs
View Full Analysis

What is Orthocell DeferredTaxAndRevenue?

Orthocell ASX:OCC +3.55% 61 DeferredTaxAndRevenue is A$0.00 Mil as of Dec. 2025. GuruFocus rates ASX:OCC with a GF Score™ of 61/100 and a GF Value™ of A$1.55 (Possible Value Trap). The stock has 2 warning signs investors should review.

Deferred Tax And Revenue represents the current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Orthocell's current deferred tax and revenue for the quarter that ended in Dec. 2025 was A$0.00 Mil.

Orthocell DeferredTaxAndRevenue Related Terms

Orthocell DeferredTaxAndRevenue Historical Data

* Premium members only.

The historical data trend for Orthocell's DeferredTaxAndRevenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Orthocell DeferredTaxAndRevenue Chart

Orthocell Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
DeferredTaxAndRevenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 2.30 2.30 2.30

Orthocell Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
DeferredTaxAndRevenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 2.30 0.00 2.30 0.00
ASX:OCC
61GF Score
Orthocell Ltd ASX:OCC
DeferredTaxAndRevenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about DeferredTaxAndRevenue →
What does a DeferredTaxAndRevenue of A$0.00 Mil mean?
Orthocell (ASX:OCC) has a DeferredTaxAndRevenue of A$0.00 Mil as of Dec. 2025. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on Orthocell.
Is Orthocell's DeferredTaxAndRevenue too high?
Orthocell's current DeferredTaxAndRevenue is A$0.00 Mil. Overall, Orthocell has a GF Score™ of 61/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Orthocell's DeferredTaxAndRevenue compare to VRTX and REGN?
Orthocell's DeferredTaxAndRevenue of A$0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good DeferredTaxAndRevenue for a Biotechnology company?
A good DeferredTaxAndRevenue depends on the Biotechnology industry context. However, DeferredTaxAndRevenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high DeferredTaxAndRevenue mean?
A high DeferredTaxAndRevenue can signal that a stock is expensive relative to its fundamentals. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on Orthocell. Orthocell's current DeferredTaxAndRevenue is A$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orthocell stock overvalued right now?
Based on GuruFocus' analysis, Orthocell (ASX:OCC) is currently considered Possible Value Trap. The stock's GF Value™ is A$1.55, compared to a current price of A$0.73 — trading 52.9% below its estimated fair value. The current DeferredTaxAndRevenue is A$0.00 Mil. Orthocell's overall GF Score™ is 61/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is DeferredTaxAndRevenue calculated?
DeferredTaxAndRevenue is calculated from a company's financial statements. For Orthocell (ASX:OCC), the current DeferredTaxAndRevenue is A$0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Orthocell (ASX:OCC) Overvalued in 2026?

Based on GuruFocus' analysis, Orthocell stock appears to be undervalued. The current stock price of A$0.73 is trading 52.9% below its estimated GF Value™ of A$1.55. GuruFocus considers Orthocell to be Possible Value Trap.

Key valuation signals for ASX:OCC:

  • DeferredTaxAndRevenue: A$0.00 Mil
  • GF Value™: A$1.55 vs. price of A$0.73 (52.9% below fair value)
  • GF Score™: 61/100 with 2 warning signs

No single metric tells the full story. See the ASX:OCC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Orthocell Business Description

Address 90 South Street, Building 191, Murdoch University, Murdoch, Perth, WA, AUS, 6150
Orthocell Ltd is a regenerative medicine company. The company is engaged in the development and commercialization of biological medical devices, cell therapies, and related technologies to address unmet clinical needs in human health in the regenerative medicine industry. Its product includes Striate plus; Remplir, which is a collagen wrap used in peripheral nerve repair; and OrthoACI, an implant used for the treatment of articular cartilage defects in the knee and ankle. It also has various other products in its pipeline, such as Tendon Cell Therapy and Collagen Medical Device Platform.
61GF Score

Get the complete analysis for ASX:OCC

DeferredTaxAndRevenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.73
Price
A$1.55
GF Value